MAPT and Alzheimer disease: All three flortaucipir PET measures and SPARE-AD predicted longitudinal changes in ADAS-Cog13 in the whole cohort (Table 2), but only SPARE-Tau predicted longitudinal changes in the Aβ+ CU participants.